Chaves, C, Marque, CR, Trzesniak, C, et al. Glutamate-N-methyl-d-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res. 2009; 42(11): 1002–1014. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0027593/. Accessed January 13, 2017.
Monte, AS, de Souza, GC, McIntyre, RS, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013; 27(11): 1032–1043. Epub ahead of print Sep 17. http://journals.sagepub.com/doi/pdf/10.1177/0269881113503506. Accessed January 13, 2017.
Hashimoto, K. Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(6): 1132; author reply 1133–1134. Epub ahead of print Apr 28.
Hashimoto, K, Ishima, T, Fujita, Y, Zhang, L. Antibiotic drug minocycline: a potential therapeutic drug for methamphetamine-related disorders [in Japanese]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2013; 48(2): 118–125.
Zhang, L, Shirayama, Y, Iyo, M, Hashimoto, K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007; 32(9): 2004–2010. Epub ahead of print Jan 17. http://www.nature.com/npp/journal/v32/n9/pdf/1301313a.pdf. Accessed January 13, 2017.
Macdonald, H, Kelly, RG, Allen, ES, Noble, JF, Kanegis, LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther. 1973; 14(5): 852–861.
Hanson, E, Healey, K, Wolf, D, Kohler, C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep. 2010; 12(6): 563–571.
Liaury, K, Miyaoka, T, Tsumori, T, et al. Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: a possible hyperbilirubinemia-induced animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 50: 184–190. Epub ahead of print Jan 2.
Seki, Y, Kato, TA, Monji, A, et al. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-γ-stimulated microglia in co-culture model. Schizophr Res. 2013; 151(1–3): 20–28. Epub ahead of print Oct 4.
Zhang, W, Narayanan, M, Friedlander, RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003; 53(2): 267–270.
Yrjanheikki, J, Tikka, T, Keinanen, R, Goldsteins, G, Chan, PH, Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999; 96(23): 13496–13500. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC23976/. Accessed January 13, 2017.
Davis, J, Moylan, S, Harvey, BH, Maes, M, Berk, M. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry. 2014; 48(6): 512–529. Epub ahead of print May 6. http://journals.sagepub.com/doi/pdf/10.1177/0004867414533012. Accessed January 13, 2017.
Hu, W, MacDonald, ML, Elswick, DE, Sweet, RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci. 2015; 1338: 38–57. Epub ahead of print Oct 14, 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363164/. Accessed January 13, 2017.
Zink, M, Correll, CU. Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Rev Clin Pharmacol. 2015; 8(3): 335–352.
Reus, GZ, Fries, GR, Stertz, L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015; 300: 141–154. Epub ahead of print May 14.
Shim, S, Shuman, M, Duncan, E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophr Res. 2015; 170(1): 226–231. Epub ahead of print Dec 22.
Fillman, SG, Weickert, TW, Lenroot, RK, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry. 2015; 21(8): 1090–1098. Epub ahead of print Jul 21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960447/. Accessed January 13, 2017.
Xiu, MH, Yang, GG, Tan, YL, et al. Decreased interleukin-10 serum levels in first-episode drug-naive schizophrenia: relationship to psychopathology. Schizophr Res. 2014; 156(1): 9–14. Epub ahead of print Apr 22.
Tuominen, HJ, Tiihonen, J, Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005; 72(2–3): 225–234.
Ventura, J, Subotnik, KL, Gitlin, MJ, et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015; 161(2–3): 407–413. Epub ahead of print Dec 8, 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308531/. Accessed January 13, 2017.
Remberk, B, Bazynska, AK, Bronowska, Z, et al. Which aspects of long-term outcome are predicted by positive and negative symptoms in early-onset psychosis? An exploratory eight-year follow-up study. Psychopathology. 2015; 48(1): 47–55. Epub ahead of print Dec 2, 2014.
Marchesi, C, Affaticati, A, Monici, A, De Panfilis, C, Ossola, P, Tonna, M. Severity of core symptoms in first episode schizophrenia and long-term remission. Psychiatry Res. 2015; 225(1–2): 129–132. Epub ahead of print Nov 11, 2014.
Galderisi, S, Bucci, P, Mucci, A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 2013; 147(1): 157–162. Epub ahead of print Apr 19.
Agid, O, Siu, CO, Pappadopulos, E, Vanderburg, D, Remington, G.. Early prediction of clinical and functional outcome in schizophrenia. Eur Neuropsychopharmacol. 2013; 23(8): 842–851. Epub ahead of print Nov 7, 2012.
Hofer, A, Baumgartner, S, Bodner, T, et al. Patient outcomes in schizophrenia, II: the impact of cognition. Eur Psychiatry. 2005; 20(5–6): 395–402.
Monji, A, Kato, TA, Mizoguchi, Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 42: 115–121. Epub ahead of print Dec 13, 2011.
Glantz, LA, Gilmore, JH, Lieberman, JA, Jarskog, LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res. 2006; 81(1): 47–63. Epub ahead of print Oct 14, 2005.
Sertan Copoglu, U, Virit, O, Hanifi Kokacya, M, et al. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients. Psychiatry Res. 2015; 229(1–2): 200–205. Epub ahead of print Jul 15.
Xu, S, Gullapalli, RP, Frost, DO. Olanzapine antipsychotic treatment of adolescent rats causes long-term changes in glutamate and GABA levels in the nucleus accumbens. Schizophr Res. 2015; 161(2–3): 452–457. Epub ahead of print Dec 5, 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308953/. Accessed January 13, 2017.
Goldstein, ME, Anderson, VM, Pillai, A, Kydd, RR, Russell, BR. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015; 18(6): pii: pyu117. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438552/. Accessed January 13, 2017.
Koprivica, V, Regardie, K, Wolff, C, et al. Aripiprazole protects cortical neurons from glutamate toxicity. Eur J Pharmacol. 2011; 651(1–3): 73–76. Epub ahead of print Nov 18, 2010.
Millan, MJ, Fone, K, Steckler, T, Horan, WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014; 24(5): 645–692. Epub ahead of print Apr 4. http://www.europeanneuropsychopharmacology.com/article/S0924-977X(14)00093-5/pdf. Accessed January 13, 2017.
Millan, MJ, Agid, Y, Brune, M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012; 11(2): 141–168.
Oya, K, Kishi, T, Iwata, N. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2014; 29(5): 483–491. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170618/. Accessed January 13, 2017.
Iwata, Y, Nakajima, S, Suzuki, T, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2015; 20(10): 1151–1160. Epub ahead of print Jun 16.
Andreasen, NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982; 39(7): 784–788.
Guy, W. ECDEU (Early Clinical Drug Evaluation) Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. https://archive.org/details/ecdeuassessmentm1933guyw. Accessed January 13, 2017.
Ghanizadeh, A, Dehbozorgi, S, OmraniSigaroodi, M, Rezaei, Z. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia: a randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov. 2014; 8(3): 211–215.
Kelly, DL, Sullivan, KM, McEvoy, JP, et al. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J Clin Psychopharmacol. 2015; 35(4): 374–381. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485552/. Accessed January 13, 2017.
Lancon, C, Auquier, P, Reine, G, Bernard, D, Toumi, M. Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). J Affect Disord. 2000; 58(2): 107–115.
Beck, AT, Alford, BA. Depression: Causes and Treatment, 2nd ed. Philadelphia: University of Pennsylvania Press; 2009.
Nuechterlein, KH, Green, MF, Kern, RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165(2): 203–213. Epub ahead of print Jan 2. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2007.07010042. Accessed January 13, 2017.
Green, MF, Nuechterlein, KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. 2004; 72(1): 1–3.
Chouinard, G, Margolese, HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005; 76(2–3): 247–265. Epub ahead of print Apr 18.
DerSimonian, R, Kacker, R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007; 28(2): 105–114. Epub ahead of print May 12, 2006.
DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177–188.
Begg, CB, Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4): 1088–1101.
Duval, S, Tweedie, R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2): 455–463.
Chaves, C, Marque, CR, Maia-de-Oliveira, JP, et al. Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia.
2015; 161(2–3): 439–445. Epub ahead of print Dec 12, 2014.
Lisiecka, DM, Suckling, J, Barnes, TR, et al. The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care—extent and mechanism (BeneMin): study protocol for a randomised controlled trial. Trials. 2015; 16: 71. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351843/. Accessed January 13, 2017.
Fekadu, A, Mesfin, M, Medhin, G, et al. Adjuvant therapy with minocycline for schizophrenia (the MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial. Trials. 2013; 14: 406. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222697/. Accessed January 13, 2017.
Chaudhry, IB, Hallak, J, Husain, N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012; 26(9): 1185–1193. Epub ahead of print Apr 23. http://journals.sagepub.com/doi/pdf/10.1177/0269881112444941. Accessed January 13, 2017.
Khodaie-Ardakani, MR, Mirshafiee, O, Farokhnia, M, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014; 215(3): 540–546. Epub ahead of print Jan 9.
Liu, F, Guo, X, Wu, R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1–3): 169–176. Epub ahead of print Feb 3.
Levkovitz, Y, Mendlovich, S, Riwkes, S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010; 71(2): 138–149. Epub ahead of print Nov 3, 2009.
Miyaoka, T, Yasukawa, R, Yasuda, H, Hayashida, M, Inagaki, T, Horiguchi, J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008; 31(5): 287–292.
Kelly, DL, Vyas, G, Richardson, CM, et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res. 2011; 133(1–3): 257–258. Epub ahead of print Aug 26.
Jhamnani, K, Shivakumar, V, Kalmady, S, Rao, NP, Venkatasubramanian, G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci. 2013; 25(1): E06–E07. http://neuro.psychiatryonline.org/doi/pdf/10.1176/appi.neuropsych.11120376. Accessed January 13, 2017.
Qurashi, I, Collins, J, Chaudhry, I, Husain, N. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. J Psychopharmacol. 2014; 28(7): 707–708. Epub ahead of print Mar 19. http://journals.sagepub.com/doi/pdf/10.1177/0269881114527358. Accessed January 13, 2017.
Carbon, M, Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl. 1): 38–52; quiz 35–37, 53.
Carvalho, AF, Miskowiak, KK, Hyphantis, TN, et al. Cognitive dysfunction in depression: pathophysiology and novel targets. CNS Neurol Disord Drug Targets. 2014; 13(10): 1819–1835.
Kane, JM, Kishimoto, T, Correll, CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3): 216–226. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799245/. Accessed January 13, 2017.
Tehrani, R, Nash-Goelitz, A, Adams, E, Dahiya, M, Eilers, D. Minocycline-induced cutaneous polyarteritis nodosa. J Clin Rheumatol. 2007; 13(3): 146–149.
Ramakrishna, J, Johnson, AR, Banner, BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol. 2009; 43(8): 787–790.
Benjamin, RW, Calikoglu, AS. Hyperthyroidism and lupus-like syndrome in an adolescent treated with minocycline for acne vulgaris. Pediatr Dermatol. 2007; 24(3): 246–249.
Ahmed, F, Kelsey, PR, Shariff, N. Lupus syndrome with neutropenia following minocycline therapy: a case report. Int J Lab Hematol. 2008; 30(6): 543–545.